A cross sectional seroprevalence study of Bartonella quintana and Bartonella henselae among patients with human immunodeficiency virus (HIV) in Iran.

Authors

Mina Latifian, Malihe Hasannezhad, Ladan Abbasian, Zahra Tahmasebi Ashtiani, Mina Arabian, Fahimeh Bagheri Amiri, Saber Esmaeili

Published in

New microbes and new infections. Volume 73. Pages 101841. Epub Sep 04, 2026.

Abstract

Bartonella henselae and Bartonella quintana are among the most clinically relevant Bartonella species infecting humans. While B. henselae is a zoonotic pathogen maintained in animal reservoirs, B. quintana is considered a human-restricted bacterium transmitted via the human body louse. Both species can cause a wide range of manifestations, particularly in immunocompromised individuals such as those with HIV/AIDS. This study aimed to estimate the prevalence of IgG and IgM seropositivity to these two species and to identify determinants of seropositivity.
This cross-sectional study included 200 participants, comprising 97 HIV-positive patients, 53 patients with AIDS, and 50 healthy individuals as the control group. IgG antibodies against B. henselae and B. quintana were measured in all participants using an indirect immunofluorescence assay (IFA). In addition, IgM antibodies were assessed in a randomly selected subset of 48 participants.
The overall seroprevalence of B. henselae and B. quintana IgG was 24.0% and 22.0%, respectively, while IgM seropositivity was 18.8% and 22.9%. No significant differences were observed in B. quintana IgG prevalence among control, HIV, and AIDS groups. Individuals with a history of drug abuse had a more than threefold increased likelihood of IgG positivity. For B. henselae, IgG prevalence was higher in the control and AIDS groups compared to HIV-positive individuals, though not statistically significant.
The significant prevalence of IgG antibodies against both Bartonella species and the presence of IgM antibodies in the selected study group, especially in HIV patients, demonstrate the clinical importance of these pathogens in at-risk populations. These findings emphasize the need for clinical vigilance in symptomatic immunocompromised patients.

PMID:
42774704
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.